Treatment Selection News Today

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.

Richard Furman, MD, outlines his strategy for addressing BTK inhibitor intolerance in CLL patients, underscoring the significance of BTK inhibitors in CLL treatment and advocating for transitioning to an alternative BTK inhibitor rather than completely discontinuing the class in cases of drug intolerance.

Oncology experts discuss findings from ELEVATE-RR and outline key considerations for combination with acalabrutinib plus obinutuzumab.

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Daniel J. Clauw, MD, shares his approach to selecting FDA approved therapeutic agents for fibromyalgia treatment and his clinical treatment strategy when first-line pharmacological therapy fails.